Page 10 - Gamida Cell News Today

Gamida Cell Ltd. (NASDAQ: GMDA) is an Israeli-based developmental biotechnology company specializing in discovering and advancing cell therapies to fight…

The DAX benchmark of the Frankfurt bourse moved higher on Tuesday amidst upbeat earnings updates that added to the positive sentiment generated by strong growth numbers from China.

Gainers Super League Gaming, Inc. (NASDAQ:SLGG) jumped 119.8% to $0.9408 in pre-market trading. LandVault and Super League disclosed a strategic...

Gamida Cell shares shot higher on Tuesday after its allogeneic cell therapy received US Food and Drug Administration (FDA) approval. Its drug candidate...

U.S. stocks traded mixed toward the end of trading, with the Dow Jones turning higher on Tuesday. The Dow traded up 0.04% to 34,000.96 while...

FDA approves Omisirge (omidubicel-onlv), a nicotinamide modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery time of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection following stem cell transplantation.

Omisirge is approved by the FDA as a new donor source for allogeneic stem cell transplant Global, randomized Phase 3 clinical trial showed faster neutrophil recovery and reduced bacterial and... | April 17, 2023

The FDA has approved omidubicel-onlv (Omisirge) to quicken the recovery of neutrophils in the body and reduce the risk of infection in adults and pediatric patients aged 12 years and older with blood cancers who are slated to undergo umbilical cord blood transplantation after a myeloablative conditioning regimen.

/PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based...

Chronic health conditions, including heart disease, neurological disorders, cancer, respiratory illnesses, stroke, and cardiovascular disorders, are...